Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "2023"

1090 News Found

Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0
News | September 12, 2024

Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0

Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign


Health Ministry releases
Policy | September 10, 2024

Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"

The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions


Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
Policy | September 10, 2024

Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting

MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions


Briefs: Wanbury and Bafna Pharmaceuticals
News | September 10, 2024

Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API


Nanoform and Celanese collaborate for biologics delivery through small implants
Biotech | September 07, 2024

Nanoform and Celanese collaborate for biologics delivery through small implants

The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics


Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
News | August 30, 2024

Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan

Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025


Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
News | August 30, 2024

Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split

The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector


Natco Pharma announces submission of TABRECTA to USFDA
Drug Approval | August 30, 2024

Natco Pharma announces submission of TABRECTA to USFDA

TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA


Shilpa Medicare receives USFDA approval for Bortezomib injection
Drug Approval | August 27, 2024

Shilpa Medicare receives USFDA approval for Bortezomib injection

Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)


Oblique Therapeutics and Eli Lilly to apply the AbiProt technology to generate antibodies to a high-value target
News | August 23, 2024

Oblique Therapeutics and Eli Lilly to apply the AbiProt technology to generate antibodies to a high-value target

This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties